These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 22396310)

  • 21. Dynamin-2 mutations linked to Centronuclear Myopathy impair actin-dependent trafficking in muscle cells.
    González-Jamett AM; Baez-Matus X; Olivares MJ; Hinostroza F; Guerra-Fernández MJ; Vasquez-Navarrete J; Bui MT; Guicheney P; Romero NB; Bevilacqua JA; Bitoun M; Caviedes P; Cárdenas AM
    Sci Rep; 2017 Jul; 7(1):4580. PubMed ID: 28676641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations in dynamin 2 cause dominant centronuclear myopathy.
    Bitoun M; Maugenre S; Jeannet PY; Lacène E; Ferrer X; Laforêt P; Martin JJ; Laporte J; Lochmüller H; Beggs AH; Fardeau M; Eymard B; Romero NB; Guicheney P
    Nat Genet; 2005 Nov; 37(11):1207-9. PubMed ID: 16227997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Satellite cells deficiency and defective regeneration in dynamin 2-related centronuclear myopathy.
    F Almeida C; Bitoun M; Vainzof M
    FASEB J; 2021 Apr; 35(4):e21346. PubMed ID: 33715228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A centronuclear myopathy-causing mutation in dynamin-2 disrupts neuronal morphology and excitatory synaptic transmission in a murine model of the disease.
    Arriagada-Diaz J; Flores-Muñoz C; Gómez-Soto B; Labraña-Allende M; Mattar-Araos M; Prado-Vega L; Hinostroza F; Gajardo I; Guerra-Fernández MJ; Bevilacqua JA; Cárdenas AM; Bitoun M; Ardiles AO; Gonzalez-Jamett AM
    Neuropathol Appl Neurobiol; 2023 Aug; 49(4):e12918. PubMed ID: 37317811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Centronuclear myopathy with cataracts due to a novel dynamin 2 (DNM2) mutation.
    Jungbluth H; Cullup T; Lillis S; Zhou H; Abbs S; Sewry C; Muntoni F
    Neuromuscul Disord; 2010 Jan; 20(1):49-52. PubMed ID: 19932620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gain-of-Function Properties of a Dynamin 2 Mutant Implicated in Charcot-Marie-Tooth Disease.
    Tassin TC; Barylko B; Hedde PN; Chen Y; Binns DD; James NG; Mueller JD; Jameson DM; Taussig R; Albanesi JP
    Front Cell Neurosci; 2021; 15():745940. PubMed ID: 34744632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel mutation in the DNM2 gene impairs dynamin 2 localization in skeletal muscle of a patient with late onset centronuclear myopathy.
    Kierdaszuk B; Berdynski M; Karolczak J; Redowicz MJ; Zekanowski C; Kaminska AM
    Neuromuscul Disord; 2013 Mar; 23(3):219-28. PubMed ID: 23374900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamin-2 mutations associated with centronuclear myopathy are hypermorphic and lead to T-tubule fragmentation.
    Chin YH; Lee A; Kan HW; Laiman J; Chuang MC; Hsieh ST; Liu YW
    Hum Mol Genet; 2015 Oct; 24(19):5542-54. PubMed ID: 26199319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new mutation in DNM2 gene in a large Italian family.
    Lopergolo D; Bocci S; Pinto AM; Valentino F; Doddato G; Ginanneschi F; Volpi N; Renieri A; Giannini F
    Neurol Sci; 2021 Jun; 42(6):2509-2513. PubMed ID: 33459893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expanding the clinical, pathological and MRI phenotype of DNM2-related centronuclear myopathy.
    Susman RD; Quijano-Roy S; Yang N; Webster R; Clarke NF; Dowling J; Kennerson M; Nicholson G; Biancalana V; Ilkovski B; Flanigan KM; Arbuckle S; Malladi C; Robinson P; Vucic S; Mayer M; Romero NB; Urtizberea JA; García-Bragado F; Guicheney P; Bitoun M; Carlier RY; North KN
    Neuromuscul Disord; 2010 Apr; 20(4):229-37. PubMed ID: 20227276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adult-onset autosomal dominant centronuclear myopathy due to BIN1 mutations.
    Böhm J; Biancalana V; Malfatti E; Dondaine N; Koch C; Vasli N; Kress W; Strittmatter M; Taratuto AL; Gonorazky H; Laforêt P; Maisonobe T; Olivé M; Gonzalez-Mera L; Fardeau M; Carrière N; Clavelou P; Eymard B; Bitoun M; Rendu J; Fauré J; Weis J; Mandel JL; Romero NB; Laporte J
    Brain; 2014 Dec; 137(Pt 12):3160-70. PubMed ID: 25260562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insights into wild-type dynamin 2 and the consequences of DNM2 mutations from transgenic zebrafish.
    Zhao M; Smith L; Volpatti J; Fabian L; Dowling JJ
    Hum Mol Genet; 2019 Dec; 28(24):4186-4196. PubMed ID: 31691805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histopathologic changes in the extraocular muscle in centronuclear myopathy with a Dynamin 2 mutation.
    Hanna N; Bouhenni R; Gupta B; Abu-Amero KK; Wollmann R; Edward DP
    Ophthalmic Genet; 2013; 34(1-2):83-6. PubMed ID: 22924779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A dog model for centronuclear myopathy carrying the most common DNM2 mutation.
    Böhm J; Barthélémy I; Landwerlin C; Blanchard-Gutton N; Relaix F; Blot S; Laporte J; Tiret L
    Dis Model Mech; 2022 Apr; 15(4):. PubMed ID: 35244154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamin 2 and human diseases.
    Durieux AC; Prudhon B; Guicheney P; Bitoun M
    J Mol Med (Berl); 2010 Apr; 88(4):339-50. PubMed ID: 20127478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imaging-based evaluation of pathogenicity by novel DNM2 variants associated with centronuclear myopathy.
    Fujise K; Okubo M; Abe T; Yamada H; Takei K; Nishino I; Takeda T; Noguchi S
    Hum Mutat; 2022 Feb; 43(2):169-179. PubMed ID: 34837441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A mutation associated with centronuclear myopathy enhances the size and stability of dynamin 2 complexes in cells.
    James NG; Digman MA; Ross JA; Barylko B; Wang L; Li J; Chen Y; Mueller JD; Gratton E; Albanesi JP; Jameson DM
    Biochim Biophys Acta; 2014 Jan; 1840(1):315-21. PubMed ID: 24016602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamin 2-related centronuclear myopathy: clinical, histological and genetic aspects of further patients and review of the literature.
    Jeub M; Bitoun M; Guicheney P; Kappes-Horn K; Strach K; Druschky KF; Weis J; Fischer D
    Clin Neuropathol; 2008; 27(6):430-8. PubMed ID: 19130742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reducing dynamin 2 expression rescues X-linked centronuclear myopathy.
    Cowling BS; Chevremont T; Prokic I; Kretz C; Ferry A; Coirault C; Koutsopoulos O; Laugel V; Romero NB; Laporte J
    J Clin Invest; 2014 Mar; 124(3):1350-63. PubMed ID: 24569376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamin 2 mutations associated with human diseases impair clathrin-mediated receptor endocytosis.
    Bitoun M; Durieux AC; Prudhon B; Bevilacqua JA; Herledan A; Sakanyan V; Urtizberea A; Cartier L; Romero NB; Guicheney P
    Hum Mutat; 2009 Oct; 30(10):1419-27. PubMed ID: 19623537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.